JP2011518153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518153A5 JP2011518153A5 JP2011504974A JP2011504974A JP2011518153A5 JP 2011518153 A5 JP2011518153 A5 JP 2011518153A5 JP 2011504974 A JP2011504974 A JP 2011504974A JP 2011504974 A JP2011504974 A JP 2011504974A JP 2011518153 A5 JP2011518153 A5 JP 2011518153A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- week
- gemcitabine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 229960005277 gemcitabine Drugs 0.000 claims 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 230000000394 mitotic effect Effects 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- 229960000928 clofarabine Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960000961 floxuridine Drugs 0.000 claims 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
- 229960002340 pentostatin Drugs 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 claims 1
- 229950006896 sapacitabine Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/005104 WO2009128805A1 (en) | 2008-04-17 | 2008-04-17 | On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518153A JP2011518153A (ja) | 2011-06-23 |
| JP2011518153A5 true JP2011518153A5 (OSRAM) | 2011-08-04 |
| JP5479453B2 JP5479453B2 (ja) | 2014-04-23 |
Family
ID=41199352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011504974A Expired - Fee Related JP5479453B2 (ja) | 2008-04-17 | 2008-04-17 | ＯＮ０１９１０．Ｎａは薬剤耐性腫瘍において化学療法剤活性を増強する |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8962614B2 (OSRAM) |
| EP (1) | EP2271339A4 (OSRAM) |
| JP (1) | JP5479453B2 (OSRAM) |
| KR (1) | KR101707669B1 (OSRAM) |
| CN (1) | CN102056607B (OSRAM) |
| AU (1) | AU2008354754B2 (OSRAM) |
| CA (1) | CA2721722C (OSRAM) |
| NZ (1) | NZ588749A (OSRAM) |
| RU (1) | RU2476239C2 (OSRAM) |
| WO (1) | WO2009128805A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101707669B1 (ko) * | 2008-04-17 | 2017-02-16 | 더 존스 홉킨스 유니버시티 | 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ |
| EP2928456B1 (en) * | 2012-12-07 | 2021-02-03 | Onconova Therapeutics, Inc. | Treatment of hematological cancer refractory to an anti-cancer agent |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| HRP20202030T1 (hr) | 2014-04-30 | 2021-02-19 | Fujifilm Corporation | Liposomska kompozicija i postupak za njeno dobivanje |
| CN113633656A (zh) | 2015-02-25 | 2021-11-12 | 柏业公司 | 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物 |
| US10669302B2 (en) * | 2015-08-28 | 2020-06-02 | Zhejianf Hisun Pharmaceutical Co., Ltd. | Crystal form of fludarabine phosphate, preparation method therefor, and application thereof |
| CN109232403A (zh) * | 2017-07-10 | 2019-01-18 | 亚宝药业集团股份有限公司 | 作为蛋白激酶抑制剂的酰胺类前药衍生物 |
| TWI874322B (zh) * | 2018-06-20 | 2025-03-01 | 日商富士軟片股份有限公司 | 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥 |
| AU2020369741B2 (en) * | 2019-10-21 | 2024-06-13 | Acura Nanomedicine Corporation | Method for treating cancers |
| EP4479042A1 (en) | 2022-02-18 | 2024-12-25 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2321454A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Gemcitabine esters and amides |
| US7037906B1 (en) * | 2000-12-22 | 2006-05-02 | Oxigene, Inc. | Methods for modulating tumor growth and metastasis |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20070197538A1 (en) * | 2004-10-07 | 2007-08-23 | Mark Nesbit | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors |
| TW200621240A (en) * | 2004-11-05 | 2006-07-01 | Salmedix Inc | Cancer treatments |
| WO2006074149A2 (en) * | 2005-01-05 | 2006-07-13 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of drug-resistant proliferative disorders |
| US7504513B2 (en) * | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
| WO2008027049A1 (en) * | 2006-08-30 | 2008-03-06 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| EP2073803B1 (en) * | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080279874A1 (en) * | 2007-05-07 | 2008-11-13 | Wyeth | Compositions and methods for modulation of plk1 kinase activity |
| KR101707669B1 (ko) * | 2008-04-17 | 2017-02-16 | 더 존스 홉킨스 유니버시티 | 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ |
-
2008
- 2008-04-17 KR KR1020107025808A patent/KR101707669B1/ko not_active Expired - Fee Related
- 2008-04-17 US US12/988,471 patent/US8962614B2/en not_active Expired - Fee Related
- 2008-04-17 NZ NZ588749A patent/NZ588749A/en not_active IP Right Cessation
- 2008-04-17 CN CN200880129775.1A patent/CN102056607B/zh not_active Expired - Fee Related
- 2008-04-17 AU AU2008354754A patent/AU2008354754B2/en not_active Ceased
- 2008-04-17 CA CA2721722A patent/CA2721722C/en not_active Expired - Fee Related
- 2008-04-17 JP JP2011504974A patent/JP5479453B2/ja not_active Expired - Fee Related
- 2008-04-17 WO PCT/US2008/005104 patent/WO2009128805A1/en not_active Ceased
- 2008-04-17 RU RU2010145048/15A patent/RU2476239C2/ru not_active IP Right Cessation
- 2008-04-17 EP EP08743127A patent/EP2271339A4/en not_active Withdrawn
-
2015
- 2015-02-17 US US14/624,057 patent/US9545418B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518153A5 (OSRAM) | ||
| Hu et al. | DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application | |
| JP2014177455A5 (OSRAM) | ||
| Miousse et al. | Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications | |
| Peters | Novel developments in the use of antimetabolites | |
| NZ602833A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| JP2012523435A5 (OSRAM) | ||
| JP2018126141A5 (OSRAM) | ||
| HRP20120419T1 (hr) | Fluoro deoksitetrahidrouridini kao inhibitori citidin deaminaze | |
| PH12015502273A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| IL186104A (en) | Phosphoramidate History of Nucleoside Compounds | |
| JP2016501513A5 (OSRAM) | ||
| RU2017120536A (ru) | Способы и композиции для модулирования экспрессии аполипопротеина (а) | |
| SG10201804571TA (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| Da Costa et al. | DNA methylation–targeted drugs | |
| JP2011501962A5 (OSRAM) | ||
| RU2010145048A (ru) | On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях | |
| Valenzuela et al. | Antimetabolite treatment for pancreatic cancer | |
| EA201500748A1 (ru) | Ингибирующие олигонуклеотиды и их применение в терапии | |
| JP2019536767A5 (OSRAM) | ||
| JP2005538129A5 (OSRAM) | ||
| JP2012522842A5 (OSRAM) | ||
| JP2017516827A5 (OSRAM) | ||
| ES2742441T3 (es) | Combinaciones de ribavirina y GDC-0449 para el tratamiento de la leucemia | |
| Hosokawa et al. | Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine |